OIS@AAO 2013

EU Commercialization Strategies

EU Commercialization Strategies

By Tom Salemi | November 14, 2013

Summit Co-Chair and Managing Director for InterWest Partners, Gilbert Kliman MD, captures the audience’s thoughts on commercialization strategies in Europe through a series of live…

Read More
2013 Ophthalmic Market – “Year in Review”

2013 Ophthalmic Market – “Year in Review”

By Tom Salemi | November 14, 2013

Emmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key…

Read More
Ophthalmic Innovation Survives and Thrives After “The Great Recession”

Ophthalmic Innovation Survives and Thrives After “The Great Recession”

By Tom Salemi | November 14, 2013

Keynote: Sustaining Innovation in Ophthalmology – “A View From the Top” David E.I. Pyott, Chairman of the Board & CEO for Allergan, delivers a keynote…

Read More
Bill Link Dives into his Perspective of Venture Overseas

Bill Link Dives into his Perspective of Venture Overseas

By Tom Salemi | November 14, 2013

William J. Link PhD, Managing Director for Versant Ventures, gives the audience at the 5th Annual Ophthalmology Innovation Summit a look into the returns on…

Read More
Jonathan Norris Predicts a Positive Cycle in the Ophthalmic Private Market

Jonathan Norris Predicts a Positive Cycle in the Ophthalmic Private Market

By Tom Salemi | November 14, 2013

Private Funding and Exit Trends Jonathan Norris, Managing Director for SVB Capital, takes the stage to share the positive sentiments on the private markets. Highlighting…

Read More
PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

By Tom Salemi | November 14, 2013

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving…

Read More
Ophthotech Introduces Their Antigen for WetAMD

Ophthotech Introduces Their Antigen for WetAMD

By Tom Salemi | November 14, 2013

David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the…

Read More
iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

By Tom Salemi | November 14, 2013

iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which…

Read More
Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

By Tom Salemi | November 14, 2013

Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s…

Read More
Physician Entrepreneurship in Ophthalmology

Physician Entrepreneurship in Ophthalmology

By Tom Salemi | November 14, 2013

Striving to reach the aspiring entrepreneurs in the crowd at the 5th Annual Ophthalmology Innovation Summit @ AAO in New Orleans, Dick Lindstrom leads an…

Read More
Ophthalmic Innovation 2013 – A View from the AAO”

Ophthalmic Innovation 2013 – “A View from the AAO”

By Tom Salemi | November 14, 2013

David Parke, CEO for the American Academy of Ophthalmology, speaks to the audience of the 5th Annual Ophthalmology Innovation Summit @ AAO, about the importance,…

Read More
Alternative Financing Strategies

Alternative Financing Strategies

By Tom Salemi | November 14, 2013

Charles Warden, Managing Director for Versant Ventures, initiates this finance focused panel by detailing the funding gap that has been referred to often at the…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.